Ulcerative colitis

This study highlights changing patterns of IBD presentation and treatment over 26 years in a large Hispanic cohort, which may affect outcomes and access-to-care discussions for Hispanic patients.

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Infliximab. The original article is from Translational gastroenterology and...

For people hospitalized with acute severe ulcerative colitis, starting a JAK inhibitor together with IV steroids right away (rather than waiting for steroids to fail) could potentially control inflammation sooner and...

Improving colon-targeted delivery of mesalamine could increase drug concentrations at inflamed tissue and reduce release in the stomach and small intestine, which may improve effectiveness and reduce off-target exposure.

This study reports early-stage lab and mouse evidence for new small molecules that target the JAK2–STAT3 immune signaling pathway, a pathway relevant to inflammation in ulcerative colitis. If findings are confirmed in...

Cure8 could only read part of this source from Internal Medicine, so this card uses cautious topic tags instead of a full summary. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and Budesonide.

Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Aminosalicylates, and Research and clinical trials. The original article is from Drug Development and Industrial...

The study describes a microbiota-responsive cytotoxic CD4+ T‑cell state that associates with worse mucosal inflammation and reduced response to common biologic therapies in ulcerative colitis, suggesting a possible...

Better delineation of dysplastic or neoplastic areas in ulcerative colitis can increase chances of complete endoscopic removal and help detect residual disease that white-light imaging misses.

People with IBD or those who had sigmoid-colon vaginoplasty may not expect neovaginal bleeding to be related to ulcerative colitis; recognizing this link can prompt appropriate evaluation and treatment. Early diagnosis...

Cure8 found this source from Gastroenterology report, but the page could not be read reliably yet. It is tagged for Ulcerative colitis, Inflammatory bowel disease, and Procedures and surgery. Open the original article...

Vitamin D appears linked to immune regulation, gut barrier health, and the microbiome—processes relevant to IBD and other intestinal disorders. Understanding this could affect how clinicians monitor and study vitamin D...

This trial tests a mushroom-derived dietary supplement in people with mild-to-moderate UC or colonic/ileal Crohn's disease, measuring symptoms, fecal biomarkers, and endoscopic activity—outcomes that matter to patients...

This registry will track how people with moderate to severe ulcerative colitis do on risankizumab in routine Japanese clinical practice, which may provide information about real-world remission rates and longer-term...

This animal study suggests Antarctic krill oil may reduce inflammation and weight loss in a mouse model of ulcerative colitis and works alongside changes in gut microbiota and metabolites—findings that could inform...

Self-management is central to living with UC, and this framework gives a structured way to design support that targets behaviors people need to manage the disease.

This paper offers a multi-layered ecological perspective on UC-associated microbiome changes that could help researchers identify which microbial functions or taxa are driven more by random processes versus selection in...

If dietary oxalate influences gut inflammation, it could be a modifiable dietary factor for some people with IBD and might help explain variability in symptoms. The study points to transporters as potential markers of...

The study introduces a novel preclinical therapeutic approach that selectively degrades HDAC6 and reduced inflammation in a mouse model of colitis, suggesting a potential new drug-discovery avenue relevant to ulcerative...

The study presents an AI method that combines endoscopic images and diagnostic text to predict histological healing in ulcerative colitis, which could help non-invasive assessment and reduce annotation effort in...

The study suggests a novel plant-derived nanoparticle approach reduced inflammation and repaired barrier function in a mouse model of colitis and changed the gut microbiome — a potential early-stage route for new IBD...

Ustekinumab treats Crohn’s disease and ulcerative colitis; a biosimilar that shows similar pharmacokinetics and safety could expand treatment options and affect availability and cost.

The study links a cellular signaling pathway that increases serotonin release from gut enterochromaffin cells to inflammation in a mouse model of ulcerative colitis. If confirmed, blocking TRPV4 could become a research...

Stigma and social support appear to meaningfully relate to quality of life for adults with IBD in Saudi Arabia. Understanding which coping strategies and support sources help could inform patient education and support...

Patients and clinicians considering sequencing of advanced UC therapies may care because this study reports differences in how long patients stayed on second-line treatment depending on the order of anti-TNF agents and...

The study suggests TIMP1 may help drive ferroptosis, inflammation, and epithelial barrier dysfunction in ulcerative colitis; targeting TIMP1 could eventually inform new therapies or biomarkers if confirmed in further...

This small case series suggests upadacitinib may induce and maintain steroid-free remission in some UC patients after tofacitinib failure, a potential option for people with refractory disease.

GLP-1 receptor agonists — drugs commonly used to treat obesity and metabolic disease — may help patients with IBD by reducing visceral fat and improving cardiometabolic health.

Based on the title and source metadata, this appears to be a clinical trial phase 2 related to Ulcerative colitis, Crohn's disease, and Research and clinical trials. The original article is from msn.com.

The study tests whether a simple blood-derived index (CRP×NLR) can help identify moderate-to-severe endoscopic inflammation when timely endoscopy is limited in hospitalized UC patients.

The work suggests that specific gut bacteria or their metabolic products (acetate, putrescine) can limit harmful E. coli expansion and reduce inflammation in a mouse model of colitis, which could inform future probiotic...

Non-invasive fecal lipid markers could help differentiate UC from CD and improve diagnostic molecular profiling in IBD if validated, which may be useful for patients and clinicians seeking less-invasive diagnostic tools.

GI infections—especially CMV—were common in this study and much more frequent in acute severe UC than in remission, suggesting testing for infections can change diagnosis and management during severe flares.

The study evaluates how well first-line 5-ASA therapy achieves modern treatment targets (endoscopic, histologic, and biomarker remission) in real-world UC patients who are clinically in remission. Patients and clinicians...

This study suggests noninvasive vagus nerve stimulation (taVNS) can reduce colonic inflammation and change immune signals regionally in a mouse model of ulcerative colitis—supporting a possible neuroimmune approach worth...

Micronutrient deficiencies are common in IBD and can worsen anemia, healing, and neurologic function. This study shows inpatient testing focuses on B12 while missing other commonly deficient nutrients (B1, B6, zinc),...

Biologics and newer small molecules have markedly changed IBD care and outcomes for many patients, but their population-level impact depends on access, cost, and how they are used. Understanding this helps patients and...

This study addresses whether being on biologic or small‑molecule IBD drugs before colorectal surgery affects short‑term postoperative complications — a practical concern for patients and clinicians planning surgery.

A targeted, pH-sensitive colon delivery system could improve effectiveness and reduce systemic side effects of drugs used for UC by releasing medication in the colon and protecting it from stomach degradation. For people...

The T&W criteria are still used to define severe UC on admission, but relying on them alone may delay recognition of steroid non‑response and escalation decisions. Integrating biomarkers, endoscopy, and imaging can help...

Distinct circulating immune signatures could help differentiate active UC from CD and suggest disease-specific pathways that might guide future biomarkers or therapies.

Better delineation of colitis‑associated neoplasia can improve the chance of complete endoscopic removal and help find residual disease that white‑light imaging may miss.

This study suggests that specific gut bacteria targeted by systemic IgG are associated with UC activity and inflammation, which could eventually help identify microbial signals linked to flares or systemic inflammation.

A colon-targeted 5-ASA pellet could improve delivery of mesalamine to the diseased colon while reducing release in the stomach; that might increase effectiveness or reduce systemic exposure compared with standard...

The probe targets azoreductase-driven hypoxia, a mechanism linked to ulcerative colitis and other hypoxia-associated diseases; a reliable real-time imaging method could help research and eventually guide treatments.

The study suggests a specific stromal and MAPK/EGFR signalling programme linked to prior anti‑TNF failure in ulcerative colitis, which could help explain why some patients are less responsive to later therapies and point...

Preclinical data suggest sodium phenylbutyrate and suramin may reduce inflammation and oxidative stress in a mouse model of ulcerative colitis, pointing to possible therapeutic mechanisms worth further study.

This study presents a targeted immunotherapy approach designed to concentrate an immune‑modulating protein (PD‑L1‑Fc) in the inflamed colon, which could in future reduce systemic side effects of biologic immunomodulators...